Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Iconovo

1,23 SEK

+2,94 %

Mindre end 1K følgere

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+2,94 %
-32,88 %
-42,76 %
-19,41 %
-67,32 %
-71,76 %
-97,31 %
-97,24 %
-96,24 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Læs mere
Markedsværdi
65 mio. SEK
Aktieomsætning
58,87 t SEK
Omsætning
2,93 mio.
EBIT %
-1.402,05 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
15.12
2025

Ekstraordinær generalforsamling '25

27.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse26.11.2025, 11.47

DNB Carnegie Access: Iconovo: Raises capital

Iconovo
Selskabsmeddelelse25.11.2025, 20.05

Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million, which is covered to 100% by subscription undertakings and guarantee commitments

Iconovo
Pressemeddelelse31.10.2025, 10.21

DNB Carnegie Access: Iconovo: New interim CEO appointed

Iconovo

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse31.10.2025, 08.35

Iconovo appoints new CEO

Iconovo
Pressemeddelelse27.10.2025, 13.13

Redeye: Iconovo (Q3 Review) - An uneventful quarter with solid cost-cutting

Iconovo
Pressemeddelelse27.10.2025, 08.00

DNB Carnegie Access: Iconovo - Rapportintervju Q3(25)

Iconovo
Pressemeddelelse24.10.2025, 16.16

DNB Carnegie Access: Iconovo: Costs down, focus sharpened – Q3 review

Iconovo
Selskabsmeddelelse24.10.2025, 06.30

QUARTERLY REPORT Q3 2025

Iconovo
Pressemeddelelse14.10.2025, 14.26

DNB Carnegie Access: Iconovo: Financial targets withdrawn

Iconovo
Selskabsmeddelelse14.10.2025, 13.37

Iconovo reworks its strategic goals

Iconovo
Selskabsmeddelelse13.8.2025, 14.00

Iconovo AB changes Certified Adviser to Tapper Partners AB

Iconovo
Pressemeddelelse15.7.2025, 08.37

Redeye: Iconovo Q2 - An undramatic report with early signs of cost reductions

Iconovo
Pressemeddelelse15.7.2025, 05.30

DNB Carnegie Access: Iconovo: Quiet Q2 but funded with a stronger ownership base

Iconovo
Selskabsmeddelelse14.7.2025, 06.30

QUARTERLY REPORT Q2 2025

Iconovo
Selskabsmeddelelse11.6.2025, 14.45

Iconovo’s rights issue is registered – conversion of BTA into shares

Iconovo
Pressemeddelelse11.6.2025, 06.30

Iconovo’s development of intranasal GLP-1 for a more convenient treatment of obesity is making significant progress

Iconovo
Selskabsmeddelelse9.6.2025, 06.15

Iconovo's nomination committee proposes the election of Christer Fåhraeus as new board member

Iconovo
Selskabsmeddelelse3.6.2025, 14.42

Iconovo announces final outcome in the rights issue

Iconovo
Selskabsmeddelelse2.6.2025, 16.50

Iconovo announces preliminary outcome of rights issue

Iconovo
Selskabsmeddelelse27.5.2025, 08.30

Last day of trading in subscription rights in Iconovo

Iconovo
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.